Status Report on HIV Drug Treatment Transition from Tenofovir/Lamivudine/Efavirenz (TLE 600mg) to Tenofovir/Lamivudine/Dolutegravir (TLD) in Malawi

Authors: Babaye Y and Nyirenda RK

DOI: 10.23880/phoa-16000118

Volume 2, Issue 1

Abstract

The Malawi Antiretroviral therapy (ART) program has over 740,000 patients on ART by end of September, 2017. This represents 71% of the estimated 1,036,000 HIV positive population [1]. In December 2017, the Ministry of Health (MoH) in Malawi made a decision to adopt a new drug combination which is Tenofovir/ Lamivudine/ Dolutegravir (TLD) as preferred first-line regimen for ART. In order to ensure adequate preparations the migration to TLD regimen is incorporated in to Malawi 2018 ART/PMTCT guideline review process with overarching goal of providing evidence-based guidance to health workers who support care and treatment services to people living with HIV (PLHIV). Pilot implementation is planned for 3000-5000 patients in the second half of 2018

Keywords:

View PDF